Werewolf Therapeutics Inc
Werewolf Therapeutics Inc (HOWL) Implied Volatility Current
HOWL implied volatility is 272%. IV Rank is 48%, placing current premiums in the middle of their 52-week range.
Read more
Tracking HOWL implied volatility helps you identify when options premiums on Werewolf Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Werewolf Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when HOWL IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Werewolf Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.
Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For HOWL, tracking metrics like HOWL IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on HOWL signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma.
The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where HOWL implied volatility sits today versus where it has been. Our scanner ranks Werewolf Therapeutics Inc implied volatility against its historical range, surfaces extremes in HOWL IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Werewolf Therapeutics Inc IV is rich or cheap — measure it, then act on it.
Implied Volatility
IV is below its typical range - premiums look reasonable for buyers.
As of September 23, 2026
Trade options with IV on your side
Track HOWL IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.
Start your 14-day free trial→